Neovacs S.A.
Research Neovacs S.A. (0LW0) on Bullrun: market cap EUR 10. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker0LW0
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 10
- Financial periodFY2024
- RevenueEUR 366.35K
- Revenue growth-31.4%
- Net income-EUR 32.91M
- Free cash flow-EUR 3.68M
- Gross margin11.6%
Valuation Snapshot
latest market cap is EUR 10.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | EUR 366.35K | -EUR 32.91M | -EUR 3.68M | 11.6% | -221.36 | EUR 435.44K | EUR 230.37K | EUR 18.06M |
| FY2023 | EUR 534.27K | -EUR 8.74M | -EUR 2.12M | 5.6% | -249812.86 | EUR 887.09K | EUR 650.59K | EUR 48.84M |
| FY2022 | EUR 2.48K | -EUR 3.55M | -EUR 4.61M | -23192.0% | -1182834.33 | EUR 43.08K | EUR 1.20M | EUR 50.17M |
| FY2021 | EUR 22.60K | -EUR 11.84M | -EUR 10.26M | -2046.1% | -47731.06 | EUR 16.25M | EUR 1.01M | EUR 43.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 10 | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neovacs S.A.'s market cap?
Neovacs S.A.'s market capitalization is EUR 10.
What does Neovacs S.A. do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies.